AdvanTIG – BGB-A317-A1217-302
The purpose of the study is to compare progression-free survival between Arm A and Arm B as assessed by investigators according to Response Evaluation Criteria in Solid Tumors Version 1.1.
Non-small cell lung cancer
A Phase 3, Randomized, Double-Blind Study of BGB-A1217, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer.
- Stage IV Non-Small Cell Lung Cancer with high PDL1 and no driver mutations
Treatment is Tizlelizumab with an Anti-TIGIT antibody vs Pembrolizumab with placebo vs Tizlelizumab with placebo at a ratio of 5:5:1. While on treatment there will be regular blood tests and scans to monitor progress. At completion of treatment the study will continue to follow your progress.